These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 34978339)

  • 21. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
    Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Tang P; Hasan MR; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; AlMukdad S; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ
    Nat Med; 2021 Dec; 27(12):2136-2143. PubMed ID: 34728831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BNT162b2 and mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 and Variants in the Urban Underserved Population.
    Weng CH; Zhou S; Saal A; Hafferty M; McGuire DC; Chan PA
    R I Med J (2013); 2023 Feb; 106(1):26-28. PubMed ID: 36706204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis.
    Rahmani K; Shavaleh R; Forouhi M; Disfani HF; Kamandi M; Oskooi RK; Foogerdi M; Soltani M; Rahchamani M; Mohaddespour M; Dianatinasab M
    Front Public Health; 2022; 10():873596. PubMed ID: 36091533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study.
    Sritipsukho P; Khawcharoenporn T; Siribumrungwong B; Damronglerd P; Suwantarat N; Satdhabudha A; Chaiyakulsil C; Sinlapamongkolkul P; Tangsathapornpong A; Bunjoungmanee P; Nanthapisal S; Tanprasertkul C; Sritipsukho N; Mingmalairak C; Apisarnthanarak A; Tantiyavarong P
    Emerg Microbes Infect; 2022 Dec; 11(1):585-592. PubMed ID: 35114893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
    Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
    Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.
    Paris C; Perrin S; Hamonic S; Bourget B; Roué C; Brassard O; Tadié E; Gicquel V; Bénézit F; Thibault V; Garlantézec R; Tattevin P
    Clin Microbiol Infect; 2021 Nov; 27(11):1699.e5-1699.e8. PubMed ID: 34265462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021.
    Harder T; Külper-Schiek W; Reda S; Treskova-Schwarzbach M; Koch J; Vygen-Bonnet S; Wichmann O
    Euro Surveill; 2021 Oct; 26(41):. PubMed ID: 34651577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Magnus MC; Håberg SE; Carlsen EØ; Kwong JC; Buchan SA; Fell DB
    Clin Infect Dis; 2023 Jan; 76(1):57-65. PubMed ID: 36071540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of mRNA COVID-19 Vaccines in Japan during the Nationwide Pandemic of the Delta Variant.
    Akaishi T; Kushimoto S; Katori Y; Sugawara N; Igarashi K; Fujita M; Kure S; Takayama S; Abe M; Kikuchi A; Ishizawa K; Abe Y; Imai H; Inaba Y; Iwamatsu-Kobayashi Y; Nishioka T; Onodera K; Ishii T
    Tohoku J Exp Med; 2022 May; 257(1):1-6. PubMed ID: 35354690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain).
    Chico-Sánchez P; Gras-Valentí P; Algado-Sellés N; Jiménez-Sepúlveda N; Vanaclocha H; Peiró S; Burgos JS; Berenguer A; Navarro D; Sánchez-Payá J;
    Prev Med; 2022 Oct; 163():107237. PubMed ID: 36057393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
    Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies.
    Xu J; Lan X; Zhang L; Zhang X; Zhang J; Song M; Liu J
    Front Public Health; 2023; 11():1165611. PubMed ID: 37325336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias.
    Andrejko KL; Pry JM; Myers JF; Mehrotra M; Lamba K; Lim E; Fukui N; DeGuzman JL; Openshaw J; Watt J; Jain S; Lewnard JA; Covid-Case-Control Study Team OBOTC
    Am J Epidemiol; 2023 Jun; 192(6):895-907. PubMed ID: 36702469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance.
    Britton A; Fleming-Dutra KE; Shang N; Smith ZR; Dorji T; Derado G; Accorsi EK; Ajani UA; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Mar; 327(11):1032-1041. PubMed ID: 35157002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States.
    Schrag SJ; Verani JR; Dixon BE; Page JM; Butterfield KA; Gaglani M; Vazquez-Benitez G; Zerbo O; Natarajan K; Ong TC; Lazariu V; Rao S; Beaver R; Ellington SR; Klein NP; Irving SA; Grannis SJ; Kiduko S; Barron MA; Midturi J; Dickerson M; Lewis N; Stockwell MS; Stenehjem E; Fadel WF; Link-Gelles R; Murthy K; Goddard K; Grisel N; Valvi NR; Fireman B; Arndorfer J; Konatham D; Ball S; Thompson MG; Naleway AL
    JAMA Netw Open; 2022 Sep; 5(9):e2233273. PubMed ID: 36156146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination.
    Mojadadi MS; Javadinia SA; Attarian F; Samami E; Sobhani M
    Front Public Health; 2022; 10():960598. PubMed ID: 36711369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.